Un homme de Rio de Janeiro qui participait aux essais de l'Université d'Oxford sur le vaccin contre le coronavirus AstraZeneca est décédé des complications de Covid-19, ont annoncé les autorités sanitaires brésiliennes. </p><div><p>L'Agence nationale de surveillance de la santé du Brésil (Agencia Nacional de Vigilancia Sanitaria, ANVISA), a déclaré mercredi qu'elle avait été informée du décès le 19 octobre, accompagnée d'une recommandation pour la poursuite de l'étude.
Brazilian media did not identify the deceased by name, claiming only that he was 28 and was a doctor or medical student.
Also on rt.com
Johnson & Johnson Suspends Coronavirus Vaccine Study, Citing ‘Unexplained Illness’ In Volunteer
It remains unclear whether the man was taking the client the AstraZeneca vaccine or was in a control group taking the placebo. Clinical data must be kept confidential to protect participants and the integrity of the study, ANVISA said in a statement.
The Anglo-Swedish multinational pharmaceutical company is conducting a third-stage trial of its Covid-19 vaccine in partnership with Oxford. The study is taking place in Brazil, UK, India and South Africa. In September, the UK study was put on hold for safety reasons, due to an unspecified illness in one of the participants.
Also on rt.com
AstraZeneca’s second volunteer reportedly suffers from rare neurological disease, but UK company says not vaccine related
The University of Oxford noted that “There were no concerns about the safety of the clinical trial” after an assessment of death in Brazil.
“The independent review, in addition to the Brazilian regulator, recommended that the trial continue”, Oxford spokesman Alexander Buxton said in a statement.
AstraZeneca stock fell sharply after the announcement, losing a dollar a share, before rising almost to previous levels during the afternoon.
Do you think your friends would be interested? Share this story!